Mordarski M, Wieczorek J
Arch Immunol Ther Exp (Warsz). 1977;25(6):757-64.
The action of two preparations (I and II) of antibiotic Wr 142 FPG on development of Ehrlich carcinoma, Nemeth-Kellner lymphoma and leukemias L 1210 and P 388 was studied. Preparation I injected s.c. daily during 14 days in doses of 10 mg/kg (1/25 LD50) inhibited growth of Ehrlich carcinoma and Nemeth-Kellner lymphoma subcutaneous tumors in R 3 mice by about 70%. The same preparation in a single i.p. injection (10 mg/kg) in FDF1 mice distinctly prolonged survival of mice inoculated with L 1210 leukemia, but was without effect on P 388 leukemia. Preparation II inhibited growth of solid tumors in doses as low as 0.1-0.2 mg/kg (about 65% inhibition), but in the same doses was ineffective against leukemias L 1210 and P 388 in CDF1 mice.
研究了两种抗生素Wr 142 FPG制剂(I和II)对艾氏癌、内梅特-凯尔纳淋巴瘤以及L 1210和P 388白血病发展的作用。制剂I在14天内每天皮下注射,剂量为10毫克/千克(1/25 LD50),可使R 3小鼠皮下的艾氏癌和内梅特-凯尔纳淋巴瘤肿瘤生长抑制约70%。同一制剂在FDF1小鼠中单次腹腔注射(10毫克/千克)可显著延长接种L 1210白血病的小鼠存活时间,但对P 388白血病无效。制剂II在低至0.1 - 0.2毫克/千克的剂量下即可抑制实体瘤生长(约65%的抑制率),但相同剂量对CDF1小鼠的L 1210和P 388白血病无效。